CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Bill Would Remove Barrier to Clinical Research for Rare Diseases by Ensuring that Clinical Trial Participants Don't Lose Critical Health Benefits
Robert J. Beall, Ph.D., today announced he will step down as president and chief executive officer of the Cystic Fibrosis Foundation, effective December 31, 2015. Preston W. Campbell III, M.D., currently the Foundation's executive vice president for medical affairs, will succeed Dr. Beall as president and CEO.
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF